CatalystMarker
← board

ACHFF

Arch Biopartners Inc.distress 0/10 · well-funded / low risk
$0.60+2%today-53% from 52w high
archbiopartners.comToronto, ONBiotechnology
Lead: Acute Kidney Injury
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
—

Price & events

-35.2% over 6M
$0.30$0.62$0.93Jan 26Apr 26Jul 26214k
CatalystRating changeDilutionFinancingdashed = today
+2.2%
1D
+0.7%
1W
+4.9%
1M
+58.9%
3M
-35.2%
6M
-53.0%
1Y
-44.1%
2Y
-42.5%
5Y
-47.0%
All

Overview

Volume
22.00K
52 Week Range
$0.30 – $1.28
Float Shares
53.11M
% Held by Insiders
19.07%
% Held by Institutions
0.00%
RVOL
0.77x
Beta
1.76

Pipeline stages · 1 programs

LSALT Peptide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-03

Pipeline · 1 trials · 1 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-03
Estimated 50%
readout ~2027-04-15
Phase 2LSALT PeptideAcute Kidney Injury, Cardiac Surgery—recruiting

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors — Acute Kidney Injury

  • EDSAEdesa Biotech, Inc.$50M · D7
  • CALCCalciMedica, Inc.$12M · D7
  • REVBREVELATION BIOSCIENCES, INC.$4M · D5
  • REVBWREVELATION BIOSCIENCES, INC.$33,222 · D6
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.